Vertex reports positive results for cystic fibrosis triple combos

Vertex reports positive results for cystic fibrosis triple combos


Vertex Pharmaceuticals Inc on Tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease. Once it has analyzed additional data and discussed development plans with regulators, Vertex said it will begin late stage studies of one or more of the triple combination regimens in the first half of 2018.



from Biotech News